Bain Capital in discussion to acquire PCI Pharma for $10 billion - Bloomberg

EditorLuke Juricic
Published 05/10/2025, 04:48 AM
© Reuters.

Investing.com -- Bain Capital is reportedly in negotiations to acquire PCI Pharma Services, according to Bloomberg, citing individuals familiar with the situation. This potential acquisition could be one of the largest private equity takeovers of the year.

The buyout firm is in talks with PCI’s current backers, which include Kohlberg & Co., Mubadala Investment Co., and Partners Group Holding AG. The proposed deal could value the Philadelphia-based drug services provider at over $10 billion, a valuation that includes debt.

An announcement regarding the deal could be made in the coming weeks, as per the sources who wished to remain anonymous due to the confidential nature of the information. However, the ongoing market fluctuations and broader macroeconomic uncertainty could disrupt the negotiations, potentially leaving PCI under its current ownership.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.